GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PureTech Health PLC (NAS:PRTC) » Definitions » COGS-to-Revenue

PRTC (PureTech Health) COGS-to-Revenue : 0.00 (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is PureTech Health COGS-to-Revenue?

PureTech Health's Cost of Goods Sold for the six months ended in Jun. 2024 was $0.00 Mil. Its Revenue for the six months ended in Jun. 2024 was $0.00 Mil.

PureTech Health's COGS to Revenue for the six months ended in Jun. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. PureTech Health's Gross Margin % for the six months ended in Jun. 2024 was N/A%.


PureTech Health COGS-to-Revenue Historical Data

The historical data trend for PureTech Health's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PureTech Health COGS-to-Revenue Chart

PureTech Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

PureTech Health Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

PureTech Health COGS-to-Revenue Calculation

PureTech Health's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0.75
=0.00

PureTech Health's COGS to Revenue for the quarter that ended in Jun. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PureTech Health  (NAS:PRTC) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

PureTech Health's Gross Margin % for the six months ended in Jun. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


PureTech Health COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of PureTech Health's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


PureTech Health Business Description

Traded in Other Exchanges
Address
6 Tide Street, Suite 400, Boston, MA, USA, 02210
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.